PT  - JOURNAL ARTICLE
AU  - Herminia L Buchelli Ramirez
AU  - Celso M Álvarez Álvarez
AU  - José J Rodríguez Reguero
AU  - Marta M García Clemente
AU  - Pere Casan Clarà
TI  - Reversible Pre-Capillary Pulmonary Hypertension Due to Dasatinib
AID  - 10.4187/respcare.02692
DP  - 2014 May 01
TA  - Respiratory Care
PG  - e77--e80
VI  - 59
IP  - 5
4099  - http://rc.rcjournal.com/content/59/5/e77.short
4100  - http://rc.rcjournal.com/content/59/5/e77.full
AB  - Pulmonary arterial hypertension and secondary pleural effusion have been reported in association with long-term therapy with the multi-tyrosine kinase inhibitor dasatinib, approved for the treatment of chronic myeloid leukemia. Here, we present the case of a 50-year-old man, diagnosed with chronic myeloid leukemia in August 2003, who developed pulmonary arterial hypertension after > 4 years of treatment with dasatinib. The complete remission of pulmonary arterial hypertension following dasatinib discontinuation suggests an etiological role of the drug in its development, although the administration of sildenafil may have played a therapeutic role.